Bio-Matrix Scientific Group Inc. Announces 20 Million Share Regen BioPharma Dividend to Be Paid to Shareholders
Dividend Is Approximately 40% Payout of Regen's Issued and Outstanding Shares
(firmenpresse) - SAN DIEGO, CA -- (Marketwired) -- 10/09/13 -- Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) today announced that its Board of Directors has authorized a distribution on a pro rata basis as a dividend in kind of 20,000,000 of the common shares of Regen BioPharma Inc. ("Dividend Shares"), a subsidiary of BMSN, to:
(a) Holders of record of the outstanding common shares of BMSN as of the record date
(b) Holders of record of the shares of any outstanding series of the preferred shares of BMSN as of the record date.
Bio-Matrix' Chairman & CEO David Koos stated, "The record date is anticipated to be set as soon as possible after the Form S-1 registering the Dividend Shares under the Securities Act of 1933 is declared effective by the United States Securities and Exchange Commission (SEC). On a pro rata basis, both common and all classes of preferred shareholders will receive this dividend. The Company expects the registration statement to be filed within the next few days with the SEC."
There are 51,610,000 currently outstanding in Regen BioPharma Inc., with Bio-Matrix Scientific Group Inc. owning 50,010,000 of these common shares.
Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. For more information refer to the company's website
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Bio-Matrix Scientific Group, Inc. and
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
619-702-1404
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 09.10.2013 - 13:11 Uhr
Sprache: Deutsch
News-ID 1271220
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SAN DIEGO, CA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 177 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bio-Matrix Scientific Group Inc. Announces 20 Million Share Regen BioPharma Dividend to Be Paid to Shareholders
"
steht unter der journalistisch-redaktionellen Verantwortung von
Bio-Matrix Scientific Group, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
